These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29052091)

  • 21. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
    Montero-Escribano P; Vila Silván C
    Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
    [No Abstract]   [Full Text] [Related]  

  • 24. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M
    Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.
    Marinelli L; Balestrino M; Mori L; Puce L; Rosa GM; Giorello L; Currà A; Fattapposta F; Serrati C; Gandolfo C; Abbruzzese G; Trompetto C
    BMJ Open; 2017 Sep; 7(9):e016843. PubMed ID: 28882919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
    Chisari CG; Solaro C; Annunziata P; Bergamaschi R; Bianco A; Bonavita S; Brescia Morra V; Bruno Bossio R; Capello E; Castelli L; Cavalla P; Costantino G; Centonze D; Cottone S; Danni MC; Esposito F; Gajofatto A; Gasperini C; Guareschi A; Lanzillo R; Lus G; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Rovaris M; Sessa E; Spinicci G; Spitaleri D; Valentino P; Zaffaroni M; Zappia M; Patti F
    J Neurol Neurosurg Psychiatry; 2020 Sep; 91(9):914-920. PubMed ID: 32661083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    Marinelli L; Mori L; Canneva S; Colombano F; Currà A; Fattapposta F; Bandini F; Capello E; Abbruzzese G; Trompetto C
    Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Marková J
    Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
    Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
    Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Gras A; Broughton J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
    Ziemssen T
    Neurodegener Dis Manag; 2019 Apr; 9(2s):1-2. PubMed ID: 30657019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
    Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
    BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó
    Eur Neurol; 2016; 75 Suppl 1():1-3. PubMed ID: 26901342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
    Meyer T; Funke A; Münch C; Kettemann D; Maier A; Walter B; Thomas A; Spittel S
    BMC Neurol; 2019 Sep; 19(1):222. PubMed ID: 31493784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
    Brady CM; DasGupta R; Dalton C; Wiseman OJ; Berkley KJ; Fowler CJ
    Mult Scler; 2004 Aug; 10(4):425-33. PubMed ID: 15327041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
    Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
    Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.